A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01101906
Recruitment Status : Terminated (Company decided not to pursue the development of this drug in this patient population at this time)
First Posted : April 12, 2010
Last Update Posted : December 12, 2012
Information provided by (Responsible Party):
Astellas Pharma Inc

Brief Summary:
This is a randomized, placebo-controlled, double-blind phase 2 study of OSI-906 or placebo at a continuous 150 mg twice daily (BID) dose.

Condition or disease Intervention/treatment Phase
Advanced Hepatocellular Carcinoma (HCC) Drug: OSI-906 Drug: Placebo Phase 2

Detailed Description:
Adult patients with advanced HCC previously treated with sorafenib will be randomized 2:1 to receive either single agent OSI-906 or placebo

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib
Study Start Date : October 2010
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Arm Intervention/treatment
Experimental: Arm A: OSI-906
150 mg BID
Drug: OSI-906
OSI-906 administered orally
Placebo Comparator: Arm B: Placebo
Placebo BID
Drug: Placebo
Matching placebo administered orally

Primary Outcome Measures :
  1. Time to progression (TTP) [ Time Frame: 20 months ]
    Time from randomization to radiological disease progression based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: 23 months ]
    Date of randomization until the documented date of death

  2. Progression Free Survival (PFS) [ Time Frame: 23 months ]
    Time from randomization to radiological disease progression based on RECIST version 1.1 assessed by investigator or death due to any cause whichever occurs first

  3. Time to Progression (including clinical progression) (TTPc) [ Time Frame: 23 months ]
    Time from randomization to progression (either radiological disease progression based on RECIST version 1.1 or symptomatic clinical progression as assessed by investigator)

  4. Disease Control Rate (DCR) [ Time Frame: 23 months ]
    Proportion of patients with a best overall response of complete response (CR), partial response (PR), or stable disease based on RECIST version 1.1 criteria

  5. Overall Response Rate [ Time Frame: 23 months ]
    Proportion of patients with a best overall response of CR or PR based on RECIST version 1.1 criteria

  6. Time to progression in patients with hepatitis B virus (HBV) and/or hepatitis C virus (HVC) [ Time Frame: 23 months ]
  7. Progression Free Survival in patients with HBV and/or HCV [ Time Frame: 23 months ]
  8. Overall Survival in patients with HBV and/or HCV [ Time Frame: 23 months ]
  9. Overall Response Rate in patients with HBV and/or HCV [ Time Frame: 23 months ]
  10. Safety assessed via physical examination, vital signs, clinical laboratory tests, electrocardiograms (ECGs) and recording adverse events [ Time Frame: 23 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed diagnosis of advanced HCC. Clinical diagnosis by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic patients is acceptable. For patients without cirrhosis histological confirmation is mandatory
  • Patients must have received prior systemic treatment for advanced HCC with sorafenib and had confirmed disease progression or had discontinued sorafenib due to a drug related toxicity
  • Patient has received their last dose of sorafenib at least 14 days prior to randomization
  • Patient has recovered from sorafenib or investigational agent related toxicity to ≤ grade 2
  • Measurable disease according to RECIST (version 1.1)
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 - 1
  • Child-Pugh Status A or B(7)
  • Barcelona Clinic Liver Cancer (BCLC) stage B/C
  • Previous local therapy (eg, surgery, radiation therapy, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) is permitted if ≥ 21 days before randomization
  • Fasting glucose ≤ 150 mg/dL (8.3 mmol/L). Concurrent use of non-insulinotropic oral antihyperglycemic therapy is permitted if the dose has been stable for ≥ 4 weeks at the time of randomization
  • Following laboratory parameters (determined by laboratory):

    • Platelets ≥ 60 x 10^9/L
    • Hemoglobin ≥ 8.5 g/dL
    • Absolute neutraphil count (ANC) ≥ 1.5 x 10^9/L
    • Potassium within normal limits (supplementation may be used)
    • Partial thrombopastin time (PTT) ≤ 2.3 x Upper Limit of Normal (ULN)
    • Magnesium within normal limits (supplementation may be used)
    • Calcium within normal limits (supplementation may be used)
  • Adequate organ function (for a HCC population):

    • Liver function test (LFT) ≤ 5 x ULN
    • Albumin ≥ 2.8 g/dL
    • Total bilirubin ≤ 2.8 mg/dL
    • Creatinine ≤ 1.5 x ULN
    • International normalized ratio (INR) ≤ 2.3
  • Estimated life expectancy ≥ 12 weeks based on an investigator assessment of recent changes in laboratory values, performance status, and other clinical criteria
  • Patients, both males and females, with reproductive potential (ie, menopausal for less than 1 year and not surgically sterilized) must agree to practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to randomization
  • Patients must provide written informed consent to participate in the study
  • Prior radiation therapy is permitted provided patients have recovered from the acute, toxic effects of radiotherapy prior to randomization. A minimum of 21 days must have elapsed between the end of radiotherapy and randomization; and
  • Prior surgery is permitted provided that the surgery was done ≤ 28 days prior to randomization and adequate wound healing has occurred prior to randomization

Exclusion Criteria:

  • Child-Pugh B (8 - 9) or C
  • Patients who are candidates for potentially curative intervention (ie, surgical resection or transplantation)
  • Type 1 diabetes mellitus or Type 2 diabetes mellitus currently requiring insulinotropic or insulin therapy
  • Prior insulin-like growth factor - 1 receptor (IGF-1R) therapy
  • Patients requiring interferon
  • Patients with uncontrolled symptomatic ascites
  • Prior investigational agent within 21 days prior to randomization
  • History of poorly controlled gastrointestinal disorders that could affect the absorption of study drug (eg, Crohn's disease, ulcerative colitis, etc)
  • History of organ allograft including liver transplant
  • Malignancy other than HCC within the past 3 years:

    • Exceptions: resected basal cell or squamous cell carcinoma of the skin, cured in situ cervical carcinoma, cured ductal carcinoma in situ of the breast, and/or cured superficial bladder cancer
  • History (within last 6 months) of significant cardiovascular disease unless the disease is well-controlled. Significant cardiac disease includes second/third degree heart block; clinically significant ischemic heart disease; superior vena cava (SVC) syndrome; poorly controlled hypertension; congestive heart failure of New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea)
  • History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is symptomatic or requires treatment (≥ grade 3), left bundle branch block (LBBB), or asymptomatic sustained ventricular tachycardia are not allowed. Patients with atrial fibrillation controlled by medication are not excluded
  • QTcF interval at screening ≥ 450 msec
  • Use of drugs that have a known risk of causing Torsades de Pointes (TdP) ('Torsades List' on category.cfm)are prohibited within 14 days prior to randomization
  • Use of the potent CYP1A2 inhibitors ciprofloxacin and fluvoxamine. Other less potent CYP1A2 inhibitors/inducers are not excluded
  • History of cerebrovascular accident (CVA) within 6 months prior to randomization or that resulted in ongoing neurologic instability
  • Active infection or serious underlying medical condition (including any type of active seizure disorder within 12 months prior to randomization) that would impair the ability of the patient to receive study drug
  • History of human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS)-related illness or serious acute or chronic illness
  • History of any psychiatric or neurologic condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide informed consent
  • Pregnant or breast-feeding females
  • Symptomatic brain metastases that are not stable, require steroids, are potentially life threatening, or that have required radiation within 28 days prior to randomization; and/or
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01101906

  Show 41 Study Locations
Sponsors and Collaborators
Astellas Pharma Inc
Study Director: Medical Director Astellas Pharma Global Development

Responsible Party: Astellas Pharma Inc Identifier: NCT01101906     History of Changes
Other Study ID Numbers: OSI-906-206
2010-018739-17 ( EudraCT Number )
First Posted: April 12, 2010    Key Record Dates
Last Update Posted: December 12, 2012
Last Verified: December 2012

Keywords provided by Astellas Pharma Inc:
Hepatocellular Carcinoma

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases